Pfizer buys generic company Hospira on a 36 x PE FY15; 30x FY16 Further evidence that investors can win out of global shakeup in Big Pharma Pfizer has paid a full price of $US17bn for Hospira which equates to a PE multiple of 36x for FY15. Pfizer has acquired Hospira, a speciality pharma and biosimilar drug company, which produces biosimilars of biologic drugs that are off patent. Consolidation among the big […]
big pharma
Consolidation in the big pharmaceuticals sector to produce better investor returns
As Big Pharma consolidates and their portfolio of drugs rationalise we expect better margins and more investment into novel therapies. This will lead to increased and higher dividends and a potential re-rating of the sector. Insync Funds Management expects big Pharma to reduce from the current eight large players over the next 12-24 months as […]
Insync Funds Management is a global equity specialist based in Sydney. Key team members own equity in the business and co-invest in the Fund alongside other investors.